Modula 5 mg is commonly marketed as tadalafil, a PDE-5 inhibitor used to treat erectile dysfunction and, in some cases, benign prostatic hyperplasia. Tadalafil is primarily metabolized by the liver enzyme CYP3A4. However, it generally does not significantly inhibit or induce major CYP enzymes, meaning it is not expected to substantially change how most other medicines are metabolized.

The more important interaction is that other medicines can affect tadalafil metabolism. Strong CYP3A4 inhibitors, such as ketoconazole and ritonavir, can increase tadalafil concentrations in the blood and potentially increase side effects. Conversely, CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and phenobarbital can lower tadalafil exposure and may reduce its effectiveness.

Studies indicate that tadalafil does not significantly alter the metabolism of medicines such as warfarin, theophylline, midazolam, or lovastatin through clinically important CYP interactions. It also has not shown a significant effect on digoxin pharmacokinetics.

Although Modula 5 mg may have limited effects on drug metabolism itself, it can still interact with medicines through blood-pressure effects. For example, combining tadalafil with nitrates can cause a dangerous drop in blood pressure, while alpha-blockers, antihypertensives, and substantial alcohol consumption can increase the risk of dizziness or low blood pressure.

Anyone taking several prescription medicines should check with a doctor or pharmacist before using tadalafil regularly.